Treatment ranges from supportive management with pyridoxine therapy in responsive cases to renal and hepatic transplantation, the latter offering a curative approach by replacing the deficient enzyme. 5 Studies of liver biopsies showed three main enzymic phenotypes: 35% of PHl patients lack both AGT catalytic activity and immunoreactivity, 24% have immunoreactive AGT without catalytic activity, and the remaining 41% of PHI patients exhibit immunoreactive protein and some AGT activity in vitro. In a significant number of the latter group, the enzyme is mistargeted from peroxisomes to mitochondria. 6 The AGXT gene, which encodes the 392 amino acid protein AGT, has been sequenced and mapped to chromosome 2q37.3.' It consists of 11 exons spanning about 10 kb. So far, four polymorphisms7-9 and seven mutations have been described in this gene.7 8 10-13 The most frequent mutation (G630A) is characterised by the mitochondrial mistargeting of AGT7 when found in the presence of the polymorphic "minor" allele, which is a combination of two single nucleotide changes, C 154T, Al 142G, a 74 bp insertion in intron 1, and a variable number tandem repeat in intron 4.6 G630A occurs in about 25% of PHI alleles, the remaining six mutations accounting for a further 4% of alleles in our series of 79 PHI patients (A C Tarn, C von Schnakenburg, G Rumsby, manuscript submitted), thus leaving a large number of alleles without any known mutation detected. In order better to define the nature of this disease and the relationship of the coding regions to protein product, we have initiated a systematic search for further mutations in the AGXT gene.
Materials and methods

PATIENTS
EDTA blood samples of 79 unrelated patients with PHI were available following referral to the University College London Hospital Primary Hyperoxaluria Service. All patients or their parents consented to DNA studies being performed. A wide variety of nationalities and ethnic groups was represented. Diagnosis of PH1 was based on measurement of AGT catalytic activity and immunoreactivity in liver biopsies (78%) or urine analysis (raised oxalate and glycolate) in combination with clinical symptoms (urolithiasis, nephrocalcinosis, end stage renal failure). All 79 samples had been screened for four polymorphisms (C 154T, Al 142G, a 74 bp insertion in intron 1, and a variable number tandem repeat in intron and seven known mutations (G243A, C320G, G367A, T576A, G630A, C682T, and The missense mutation T853C in exon 7 was found in nine of 79 PH1 patients and a further affected sib. With an allelic frequency of 9% this is the second most common mutation after G630A. Therefore, it is of great significance for our understanding of this disease.
The segregation of the T853C mutation with disease in one family supports the causal role of this mutation in PH 1. The finding of three other mutations in the same exon with similar enzymic characteristics, namely very little catalytic activity and only a small amount of immunoreactive protein present, is further proof of the importance of this gene region in enzyme or mRNA stability.
Our knowledge about the structure-function relationship of the human AGXT gene to the AGT protein is mainly limited to sequences which determine the intracellular location of the enzyme: a weak mitochondrial targeting sequence is present at the amino-terminal end of the protein in those people carrying a Pro 11 Leu polymorphism7 and a peroxisomal targeting sequence has been identified at the C-terminal end of the enzyme. '9 The putative pyridoxine binding site has been located at residue Lys20925 and an evolutionarily highly 
